About this trial
The main treatment for Parkinson's disease is a medication called levodopa. Levodopa has to be absorbed from the gut and travel to the brain to work, but a naturally occurring enzyme in the lining of the stomach, called dopamine decarboxylase (AADC), can break some of it down before it ever reaches the brain. We do not yet know whether people whose stomachs have more of this enzyme absorb less of their levodopa dose, have worsened gastrointestinal (GI) symptoms associated with levodopa intake, and whether that affects how well the medication controls their movement symptoms. This research may help doctors understand why levodopa works better in some people with Parkinson's disease than others, which could help improve treatment in future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Parkinson's disease
Gastric biopsies previously obtained during clinically-indicated EGD procedure
Taking dopamine replacement therapy currently
Disqualifiers
No history of Parkinson's disease
Trial design
Parallel
Treatments tested in this trial
Levodopa (L-dopa)
Druglevodopa will be administered to all participants in this single arm study
Treatment groups
Trial outcomes
Primary outcomes
levodopa pharmacodynamics
Peripheral levodopa levels will be assessed via blood draw to determine time (in minutes) to reach maximum concentration in the blood. Lower Tmax indicates quicker bioavailability.
Secondary outcomes
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score
Neurological symptoms will be assessed during study period. A lower score indicates less severe symptoms.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beth Israel Deaconess Medical Center
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
This trial is not recruiting at the moment. You can still explore other options: